Literature DB >> 33515351

The impact of sex and age on distribution of metastases in patients with renal cell carcinoma.

Giuseppe Rosiello1,2, Angela Pecoraro3,4, Marina Deuker3,5, Lara Franziska Stolzenbach3,6, Thomas Martin3, Zhe Tian3, Alessandro Larcher7, Umberto Capitanio7, Francesco Montorsi7, Shahrokh F Shariat8,9, Anil Kapoor10, Fred Saad3, Alberto Briganti7, Pierre I Karakiewicz3.   

Abstract

BACKGROUND: Our objective was to investigate age and sex-related discrepancies on distribution of metastases in patients with metastatic renal cell carcinoma (RCC).
METHODS: Within the National Inpatient Sample database (2008-2015) we identified 9607 patients with metastatic RCC. Trend test and Chi-square test analyses were used to evaluate the relationship between age and site of metastases, according to sex.
RESULTS: Of 9607 patients with metastatic RCC, 6344 (65.9%) were men and 3263 (34.1%) were women. Thoracic, abdominal, bone and brain metastases were present in 51.1 vs. 52.8%, 42.6 vs. 44.3%, 29.9 vs. 29.2% and 8.6 vs. 8.8% of men vs. women, respectively. Increasing age was associated with decreasing rates of thoracic (from 55.5 to 48.5%) and brain (from 8.6 to 5.8%) metastases in men and with decreasing rates of abdominal (from 48.3 to 39.6%), bone (from 32.6 to 24.9%) and brain (from 8.8 to 5.4%) metastases in women. (all p < 0.05). Rates of concomitant metastatic sites also decreased with increasing age, from 57.1 to 50.8% in men and from 54.1 to 50.2% in women.
CONCLUSIONS: Important age and sex-related differences exist in the distribution of RCC metastases. The distribution of metastases is marginally different between sexes. Specifically, more advanced age is associated with lower rates of thoracic and brain metastases in men and with lower rates of abdominal, bone and brain metastases in women. Age and sex should be take into consideration into the staging management strategy, as well as into the follow-up strategy of patients with metastatic RCC.

Entities:  

Keywords:  Advanced kidney cancer; Epidemiology; Kidney cancer; Location of disease; National inpatient sample database

Year:  2021        PMID: 33515351     DOI: 10.1007/s10147-021-01874-3

Source DB:  PubMed          Journal:  Int J Clin Oncol        ISSN: 1341-9625            Impact factor:   3.402


  20 in total

Review 1.  Renal cancer.

Authors:  Umberto Capitanio; Francesco Montorsi
Journal:  Lancet       Date:  2015-08-25       Impact factor: 79.321

2.  Survival and Complication Rates of Metastasectomy in Patients With Metastatic Renal Cell Carcinoma Treated Exclusively With Targeted Therapy: A Combined Population-based Analysis.

Authors:  Carlotta Palumbo; Angela Pecoraro; Sophie Knipper; Giuseppe Rosiello; Zhe Tian; Shahrokh F Shariat; Claudio Simeone; Alberto Briganti; Fred Saad; Alfredo Berruti; Alessandro Antonelli; Pierre I Karakiewicz
Journal:  Anticancer Res       Date:  2019-08       Impact factor: 2.480

Review 3.  Individualised Indications for Cytoreductive Nephrectomy: Which Criteria Define the Optimal Candidates?

Authors:  Alessandro Larcher; Christopher J D Wallis; Axel Bex; Michael L Blute; Vincenzo Ficarra; Arnaud Mejean; Jose A Karam; Hendrik Van Poppel; Sumanta K Pal
Journal:  Eur Urol Oncol       Date:  2019-05-18

Review 4.  Role of Active Surveillance for Localized Small Renal Masses.

Authors:  Maria Carmen Mir; Umberto Capitanio; Riccardo Bertolo; Idir Ouzaid; Maciej Salagierski; Maximilian Kriegmair; Alessandro Volpe; Michael A S Jewett; Alexander Kutikov; Phillip M Pierorazio
Journal:  Eur Urol Oncol       Date:  2018-05-26

5.  Cytoreductive Nephrectomy in Metastatic Patients with Signs or Symptoms: Implications for Renal Cell Carcinoma Guidelines.

Authors:  Alessandro Larcher; Giuseppe Fallara; Giuseppe Rosiello; Chiara Re; Gianfranco Baiamonte; Stefano Agnesi; Daniele Cignoli; Gianmarco Colandrea; Giuseppe Basile; Alberto Briganti; Andrea Salonia; Roberto Bertini; Francesco Montorsi; Umberto Capitanio
Journal:  Eur Urol       Date:  2020-06-02       Impact factor: 20.096

6.  Renal cell carcinoma incidence rates and trends in young adults aged 20-39 years.

Authors:  Carlotta Palumbo; Angela Pecoraro; Giuseppe Rosiello; Stefano Luzzago; Marina Deuker; Franziska Stolzenbach; Zhe Tian; Shahrokh F Shariat; Claudio Simeone; Alberto Briganti; Fred Saad; Alfredo Berruti; Alessandro Antonelli; Pierre I Karakiewicz
Journal:  Cancer Epidemiol       Date:  2020-06-22       Impact factor: 2.984

7.  Clinical Stage Migration and Survival for Renal Cell Carcinoma in the United States.

Authors:  Hiten D Patel; Mohit Gupta; Gregory A Joice; Arnav Srivastava; Ridwan Alam; Mohamad E Allaf; Phillip M Pierorazio
Journal:  Eur Urol Oncol       Date:  2018-09-25

Review 8.  Sequencing and Combination of Systemic Therapy in Metastatic Renal Cell Carcinoma.

Authors:  Guillermo de Velasco; Axel Bex; Laurence Albiges; Thomas Powles; Brian I Rini; Robert J Motzer; Daniel Y C Heng; Bernard Escudier
Journal:  Eur Urol Oncol       Date:  2019-08-01

Review 9.  Epidemiology of Renal Cell Carcinoma.

Authors:  Umberto Capitanio; Karim Bensalah; Axel Bex; Stephen A Boorjian; Freddie Bray; Jonathan Coleman; John L Gore; Maxine Sun; Christopher Wood; Paul Russo
Journal:  Eur Urol       Date:  2018-09-19       Impact factor: 20.096

10.  The impact of intraoperative bleeding on the risk of chronic kidney disease after nephron-sparing surgery.

Authors:  Giuseppe Rosiello; Alessandro Larcher; Giuseppe Fallara; Giuseppe Basile; Daniele Cignoli; Gianmarco Colandrea; Chiara Re; Francesco Trevisani; Pierre I Karakiewicz; Andrea Salonia; Roberto Bertini; Alberto Briganti; Francesco Montorsi; Umberto Capitanio
Journal:  World J Urol       Date:  2020-10-29       Impact factor: 4.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.